Citations

Showing 10 of 108081 citations.

Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy
Bahr, Tyler , Bakri, Sophie J. , Bahr, Tyler A

Mayo Clinic

Life | April 28, 2023 | Volume: 13 | Issue: 5 | Pages: 1098

10.3390/life13051098 | PMID 37240743 Get It

Diabetic retinopathy (DR) is a microvascular disease caused by poorly controlled blood glucose, and it is a leading cause of vision loss in people with diabetes. In this review we discuss the current management of DR with particular focus on the use of intraocular anti-vascular endothelial growth factor (anti-VEGF) agents. Intraocular anti-VEGF agents were first studied in the 1990s, and now several of these agents are either FDA approved or used off-label as first-line treatments for DR. Recent evidence shows that anti-VEGF agents can halt the progression of markers of DR severity, reduce the risk of DR worsening, and reduce the onset of new macular edema. These significant benefits have been demonstrated in patients with proliferative DR and the milder nonproliferative DR (NPDR). A wealth of evidence from recent trials and meta-analyses has detailed the intraoperative and postoperative benefits of adjunctive anti-VEGF therapy prior to pars plana vitrectomy (PPV) for proliferative DR with vitreous hemorrhage. In this review, we also discuss literature comparing various anti-VEGF injection regimens including monthly, quarterly, as-needed, and treat and extend protocols. Combination protocols with panretinal photocoagulation (PRP) or PPV are also discussed. Current evidence suggests that anti-VEGF therapies are effective therapy for NPDR and PDR and may also provide significant benefits when used adjunctively with other DR treatment modalities such as PRP or PPV.
Metabolic Syndrome Induces Epigenetic Alterations in Mitochondria-Related Genes in Swine Mesenchymal Stem Cells
Rajagopalan, Kamalnath Sankaran, Kazeminia, Sara , Glasstetter, Logan M., Farahani, Rahele A., Zhu, Xiangyang , Jordan, Kyra L., Chade, Alejandro , Lerman, Lilach O. , Rajagopalan, Kamalnath S, Lerman, Lilach O , Eirin, Alfonso , Kazeminia, Sara , Tang, Hui Ru , Lerman, Amir , Eirin, Alfonso

Mayo Clinic

Cells | April 28, 2023 | Volume: 12 | Issue: 9 | Pages: 1274

10.3390/cells12091274 | PMID 37174674 Get It

Autologous mesenchymal stem/stromal cells (MSCs) have demonstrated important therapeutic effects in several diseases. Cardiovascular risk factors may impair MSC mitochondrial structure and function, but the underlying mechanisms remain unknown. We hypothesized that metabolic syndrome (MetS) induces epigenetic alterations in mitochondria-related genes in swine MSCs. Pigs were fed a Lean or MetS diet (n = 6 each) for 16 weeks. MSCs were collected from subcutaneous abdominal fat, and DNA hydroxymethylation (5 hmC) profiles of mitochondria-related genes (MitoCarta-2.0) were analyzed by hydroxymethylated DNA immunoprecipitation and next-generation sequencing (hMeDIP-seq) in Lean- and MetS-MSCs untreated or treated with the epigenetic modulator vitamin (Vit)-C (n = 3 each). Functional analysis of genes with differential 5 hmC regions was performed using DAVID6.8. Mitochondrial structure (electron microscopy), oxidative stress, and membrane potential were assessed. hMeDIP-seq identified 172 peaks (associated with 103 mitochondrial genes) with higher and 416 peaks (associated with 165 mitochondrial genes) with lower 5 hmC levels in MetS-MSCs versus Lean-MSCs (≥2-fold, p < 0.05). Genes with higher 5 hmC levels in MetS + MSCs were primarily implicated in fatty acid metabolism, whereas those with lower 5 hmC levels were associated with electron transport chain activity. Vit-C increased 5 hmC levels in mitochondrial antioxidant genes, improved mitochondrial structure and membrane potential, and decreased oxidative stress. MetS alters 5 hmC levels of mitochondria-related genes in swine MSCs. Vit-C modulated 5 hmC levels in these genes and preserved mitochondrial structure and function in MetS-MSCs. These observations may contribute to development of strategies to overcome the deleterious effects of MetS on MSCs.
Adverse childhood experiences and sexual dysfunction in midlife women: Is there a link?
Saadedine, Mariam , Kingsberg, Sheryl A. , Kuhle, Carol L. , Mara, Kristin C. , Kapoor, Ekta , Faubion, Stephanie, Enders, Felicity , Kuhle, Carol, Mara, Kristin, Mara, Kristin C , Faubion, Stephanie S. , Kling, Juliana M. , Kapoor, Ekta

Mayo Clinic

The Journal of Sexual Medicine | April 27, 2023 | Volume: 20 | Issue: 6 | Pages: 792-799

10.1093/jsxmed/qdad053 | PMID 37105936 Get It

Abstract Background One in 3 children has had at least 1 adverse childhood experience (ACE), and ACEs have been associated with multiple medical and psychiatric morbidities in women later in life, including greater menopause symptom burden. Aim To evaluate the association between ACEs and female sexual dysfunction (FSD) in midlife women. Methods A cross-sectional analysis from DREAMS—the Data Registry on Experiences of Aging, Menopause, and Sexuality—was conducted with questionnaires completed by women aged 40 to 65 years who presented to a women’s health clinic at Mayo Clinic in Rochester, Minnesota, from May 2015 to December 2016. History of ACEs was obtained with the validated ACE questionnaire. FSD was assessed by the Female Sexual Function Index and the Female Sexual Distress Scale–Revised. Outcomes The association between ACEs and FSD (defined as Female Sexual Function Index score ≤26.55 and Female Sexual Distress Scale–Revised score ≥11) was evaluated via a multivariable logistic regression model, adjusting for age, menopause status, hormone therapy use, anxiety, depression, relationship satisfaction, hot flash severity, and history of abuse in the past year. Results Women (N = 1572) had a mean age of 53.2 years. Overall 59% reported having at least 1 ACE. When compared with no ACEs, a history of ≥4 ACEs significantly increased the odds of not being sexually active (odds ratio, 1.83; 95% CI, 1.30-2.57; P &lt; .001). Among sexually active women, the proportion of women with FSD increased sequentially as the number of ACEs increased. In the univariate analysis, a history of ≥4 ACEs significantly increased the odds of FSD as compared with no ACEs (odds ratio, 2.12; 95% CI, 1.50-2.99; P &lt; .001). The association remained statistically significant in the multivariable analysis after adjusting for confounders (odds ratio, 1.75; 95% CI, 1.15-2.68; P = .009). Clinical Implications The findings highlight an opportunity for clinicians to screen for ACEs in women with sexual dysfunction and offer appropriate treatment and counseling as indicated. Strengths and Limitations Strengths of the study include the large cohort, the use of validated tools for assessment of ACEs and FSD, and the adjustment for multiple potential confounding factors. Limitations include the cross-sectional study design, recall bias in reporting ACEs and recent abuse, and the low representation of racially and ethnically diverse women in the cohort. Conclusion The study demonstrates an increased risk of sexual inactivity and sexual dysfunction in midlife women who experienced childhood adversity. The sexual dysfunction in women with ACEs seems to be independent of other factors that potentially affect female sexual function in midlife.
Engaging Adolescents and Young Adults in Decisions About Return of Genomic Research Results: a mixed-methods longitudinal clinical trial protocol
Blumling, Amy A. , Prows, Cynthia A. , Childers-Buschle, Kristin , Dufendach, Kevin R., Kovacic, Melinda Butsch , Brinkman, Bill, McGowan, Michelle, McGowan, Michelle L. , Martin, Lisa Joy , Lynch, John , Lipstein, Ellen A. , Myers, Melanie F.

Mayo Clinic

No container title available | April 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2819191/v1 | PMID 37162875 Get It

Abstract Background To protect minors’ future autonomy, professional organizations have historically discouraged returning predictive adult-onset genetic test results and carrier status to children. Recent clinical guidance diverges from this norm, suggesting that when minors have genomic sequencing performed for clinical purposes, parents and children should have the opportunity to learn secondary findings, including for some adult-onset conditions. While parents can currently opt in or out of receiving their child’s secondary findings, the American Society of Human Genetics Workgroup on Pediatric Genetic and Genomic Testing suggests including adolescents in the decision-making process. However, it is not clear what factors young people consider when given the opportunity to learn genetic findings for themselves. We are examining adolescents’, young adults’, and parents’ (if applicable) decisions about learning genomic information for the adolescent. Methods We are enrolling assenting (ages 13–17) adolescents and consenting (ages 18–21) young adults in a prospective genomic screening study to assess the choices they make about receiving individual genomic results. Participants use an online tool to indicate whether they want to learn their personal genetic risk for specific preventable, treatable, and adult-onset conditions, as well as carrier status for autosomal recessive conditions. We are examining 1) how choices differ between adolescent and young adult cohorts (as well as between adolescents/young adults and parents) and 2) decisional conflict and stability across study timepoints. Results are returned based on participants’ choices. Qualitative interviews with a subset of participants explore decisional stability, adolescent/young adult engagement with parents in decision-making, and the impact of learning pathogenic/likely pathogenic and carrier results. Discussion This study explores decision making and decision stability between adolescents and parents (where applicable), as well as the ethical implications and impact of return of clinical-grade genetic research results to adolescents and young adults. The results of this study will contribute empirical evidence to support best practices and guidance on engaging young people in genetic research studies and clinical care that offer return of results. Trial Registration: ClinicalTrials.gov Identifier: NCT04481061. Registered 22 July 2020.
Analysis of microvasculature morphological features for prediction of metastatic lymph nodes in breast cancer patients via contrast-free ultrasound imaging
Sabeti, Soroosh , Ferroni, Giulia, Fazzio, Robert T. , Larson, Nicholas B. , Fatemi, Mostafa , Alizad, Azra

Mayo Clinic

The Journal of the Acoustical Society of America | April 27, 2023 | Volume: 153 | Issue: 3_supplement | Pages: A137-A137

10.1121/10.0018422 Get It

Axillary lymph nodes (ALNs) are generally among the first to be impacted by the metastatic spread of breast tumors. Consequently, evaluating their condition is of great importance as the removal of affected ALNs can potentially curtail the further spread of cancer cells to other parts of the body. Conventional ultrasound imaging suffers from low sensitivity and specificity and does not provide a comprehensive picture of the status of the node. In this work, we utilize an ultrasound microvessel imaging technique to visualize vascular structures within ALNs and, through several image processing steps, characterize the morphology of these structures. Several morphological metrics are used as biomarkers to differentiate between reactive and metastatic lymph nodes of patients with suspicious ALNs. A group of 68 patients is included in this study. Pathology examination results are used as the gold-standard reference for data labeling. A support vector machine (SVM) model is trained, and its performance is evaluated. Statistical analysis of the discriminative potential of individual biomarkers and receiver operating characteristic (ROC) curve analysis of the trained model are presented. Preliminary results suggest that a sensitivity of 0.88, specificity of 0.88, and area under the curve of 0.94 are achievable. Work supported by NIH-R01CA239548.
Listening to Learners to Prepare for the Future: A Mayo Clinic College of Medicine and Science Benchmarking Survey
Marks, Lisa , Brigham, Tara , Chelf, Cynthia , Marks, Lisa A , Brigham, T J , Chelf, Cynthia J

Mayo Clinic

Medical Reference Services Quarterly | April 27, 2023 | Volume: 42 | Issue: 2 | Pages: 202-210

10.1080/02763869.2023.2194148 | PMID 37104258 Get It

Extratesticular Scrotal Masses and Pseudomasses
Smith, Mathew V. , Young, Scott W. , Patel, Bhavik N. , Yano, Motoyo , Fananapazir, Ghaneh , Smith, Mathew , Young, Scott W , Patel, Bhavik , Fananapazir, Ghaneh , Tan, Nelly

Mayo Clinic

RadioGraphics | April 27, 2023 | Volume: 43 | Issue: 5 | Pages: No page available

10.1148/rg.220080 | PMID 37104123 Get It

Impact of Artificial Intelligence System and Volumetric Density on Risk Prediction of Interval, Screen-Detected, and Advanced Breast Cancer
Vachon, Celine M. , Scott, Christopher G. , Norman, Aaron D. , Khanani, Sadia, Jensen, Matthew R. , Hruska, Carrie B. , Brandt, Kathleen R. , Winham, Stacey J. , Kerlikowske, Karla , Khanani, Sadia A, Winham, Stacey J , Hruska, Carrie B , Scott, Christopher , Norman, Aaron D , Kerlikowske, Karla M , Vachon, Celine M.

Mayo Clinic

Journal of Clinical Oncology | April 27, 2023 | Volume: 41 | Issue: 17 | Pages: 3172-3183

10.1200/jco.22.01153 | PMID 37104728 Get It

PURPOSE Artificial intelligence (AI) algorithms improve breast cancer detection on mammography, but their contribution to long-term risk prediction for advanced and interval cancers is unknown. METHODS We identified 2,412 women with invasive breast cancer and 4,995 controls matched on age, race, and date of mammogram, from two US mammography cohorts, who had two-dimensional full-field digital mammograms performed 2-5.5 years before cancer diagnosis. We assessed Breast Imaging Reporting and Data System density, an AI malignancy score (1-10), and volumetric density measures. We used conditional logistic regression to estimate odds ratios (ORs), 95% CIs, adjusted for age and BMI, and C-statistics (AUC) to describe the association of AI score with invasive cancer and its contribution to models with breast density measures. Likelihood ratio tests (LRTs) and bootstrapping methods were used to compare model performance. RESULTS On mammograms between 2-5.5 years prior to cancer, a one unit increase in AI score was associated with 20% greater odds of invasive breast cancer (OR, 1.20; 95% CI, 1.17 to 1.22; AUC, 0.63; 95% CI, 0.62 to 0.64) and was similarly predictive of interval (OR, 1.20; 95% CI, 1.13 to 1.27; AUC, 0.63) and advanced cancers (OR, 1.23; 95% CI, 1.16 to 1.31; AUC, 0.64) and in dense (OR, 1.18; 95% CI, 1.15 to 1.22; AUC, 0.66) breasts. AI score improved prediction of all cancer types in models with density measures ( P LRT values < .001); discrimination improved for advanced cancer (ie, AUC for dense volume increased from 0.624 to 0.679, Δ AUC 0.065, P = .01) but did not reach statistical significance for interval cancer. CONCLUSION AI imaging algorithms coupled with breast density independently contribute to long-term risk prediction of invasive breast cancers, in particular, advanced cancer.
P erspective : Teenagers and the sleep paradox
Ramar, Sreya, Lloyd, Robin M.

Mayo Clinic

Journal of Clinical Sleep Medicine | April 27, 2023 | Volume: 19 | Issue: 8 | Pages: 1569-1571

10.5664/jcsm.10636 | PMID 37185050 Get It

Are clinical trials for insomnia recruiting real-world patients?
Golebiowski, Raphael, Kolla, Bhanu Prakash , Mansukhani, Meghna P.

Mayo Clinic

Journal of Clinical Sleep Medicine | April 27, 2023 | Volume: 19 | Issue: 8 | Pages: 1553-1555

10.5664/jcsm.10640 | PMID 37185063 Get It